

# COPD: Disease Insights and Market Forecasts to 2024

<https://marketpublishers.com/r/C8C7A2488AEEN.html>

Date: March 2018

Pages: 120

Price: US\$ 5,000.00 (Single User License)

ID: C8C7A2488AEEN

## Abstracts

Delivery time for this report is 5 days

“COPD: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of COPD disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for COPD, drug wise in \$ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024.

Geographies covered:

US

Germany

France

Italy

Spain

UK

Japan

Australia

Canada

### Disease Indication Overview:

This section of the report gives the overview of COPD disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of COPD disease. Further details on the profile of COPD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for COPD disease.

### Epidemiology Forecasts to 2024:

This section of the report provides the overview of COPD diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

### Drugs Overview and Attribute Analysis:

This part of the report highlights the importance of factors influencing the physician prescription decisions in COPD disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in COPD disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the COPD market.

The report further conducts a detailed drug attribute analysis of the drugs currently prescribed or expected to be prescribed in the disease on the parameters of Efficacy, Safety and Tolerability, Convenience of Monitoring and Dosing and Drug's coverage of the target patient pool.

### Drugs and Market Forecast to 2024:

The report in its last section provides sales and patient numbers forecast for the overall COPD market and drug wise forecasts from 2015 till 2024 at Global level and in the US, EU5, Australia and Canada markets. The forecasts are developed based on the

detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc. The forecast models are at the country level and can be developed at the regional level as well.

#### Why Purchase the Report:

Robust Market and Drug forecast available at country level

Forecast in terms of both \$ sales and Patient Numbers

Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool

Detailed Drug Attribute analysis on multiple Clinical Parameters

Multiple Countries coverage

Current Marketed and Pipeline Drugs coverage

Detailed Disease Insights coverage

## Contents

Table of Contents

1.1 List of Tables

1.2 List of Figures

### **2 EXECUTIVE SUMMARY**

2.1 Key Metrics

### **3 DISEASE OVERVIEW**

3.1 Disease Definition

3.2 Disease Etiology and Pathophysiology

3.2.1 Etiology

3.2.2 Pathophysiology

3.2.3 Impact on Quality of Life

3.3 Symptoms of the Disease

3.4 Disease Diagnosis

3.5 Treatment Guidelines

3.6 Key unmet needs

### **4 DISEASE EPIDEMIOLOGY**

4.1 Patient Number projections by Country

4.1.1 France

4.1.2 Germany

4.1.3 Italy

4.1.4 Spain

4.1.5 United Kingdom

4.1.6 United States

4.1.7 Japan

### **5 PHYSICIAN'S INSIGHTS**

5.1 Factors impacting a physician's prescription decision:

5.1.1 Efficacy

5.1.2 Safety

5.1.3 Monitoring requirements

#### 5.1.4 Pricing and Reimbursement

## **6 COMPETITIVE ASSESSMENT AND ATTRIBUTE ANALYSIS – KEY THERAPIES**

### 6.1 Spiriva

#### 6.1.1 Overview

#### 6.1.2 Patent Information

#### 6.1.3 Clinical Status and Trial Details

#### 6.1.4 Attribute Analysis

#### 6.1.5 Impact of Drug on the market

### 6.2 Tudorza Pressair

#### 6.2.1 Overview

#### 6.2.2 Patent Information

#### 6.2.3 Clinical Status and Trial Details

#### 6.2.4 Attribute Analysis

#### 6.2.5 Impact of Drug on the market

### 6.3 Seebri Neohaler

#### 6.3.1 Overview

#### 6.3.2 Patent Information

#### 6.3.3 Clinical Status and Trial Details

#### 6.3.4 Attribute Analysis

#### 6.3.5 Impact of Drug on the market

### 6.4 Incruse Ellipta

#### 6.4.1 Overview

#### 6.4.2 Patent Information

#### 6.4.3 Clinical Status and Trial Details

#### 6.4.4 Attribute Analysis

#### 6.4.5 Impact of Drug on the market

### 6.5 Onbrez

#### 6.5.1 Overview

#### 6.5.2 Patent Information

#### 6.5.3 Clinical Status and Trial Details

#### 6.5.4 Attribute Analysis

#### 6.5.5 Impact of Drug on the market

### 6.6 Striverdi Respimat

#### 6.6.1 Overview

#### 6.6.2 Patent Information

#### 6.6.3 Clinical Status and Trial Details

#### 6.6.4 Attribute Analysis

- 6.6.5 Impact of Drug on the market
- 6.7 Advair/Seretide
  - 6.7.1 Overview
  - 6.7.2 Patent Information
  - 6.7.3 Clinical Status and Trial Details
  - 6.7.4 Attribute Analysis
  - 6.7.5 Impact of Drug on the market
- 6.8 Symbicort Turbuhaler
  - 6.8.1 Overview
  - 6.8.2 Patent Information
  - 6.8.3 Clinical Status and Trial Details
  - 6.8.4 Attribute Analysis
  - 6.8.5 Impact of Drug on the market
- 6.9 Breo Ellipta
  - 6.9.1 Overview
  - 6.9.2 Patent Information
  - 6.9.3 Clinical Status and Trial Details
  - 6.9.4 Attribute Analysis
  - 6.9.5 Impact of Drug on the market
- 6.10 Ultibro/Utibron
  - 6.10.1 Overview
  - 6.10.2 Patent Information
  - 6.10.3 Clinical Status and Trial Details
  - 6.10.4 Attribute Analysis
  - 6.10.5 Impact of Drug on the market
- 6.11 Anoro Ellipta
  - 6.11.1 Overview
  - 6.11.2 Patent Information
  - 6.11.3 Clinical Status and Trial Details
  - 6.11.4 Attribute Analysis
  - 6.11.5 Impact of Drug on the market
- 6.12 Brimica Genuair/Duaklir
  - 6.12.1 Overview
  - 6.12.2 Patent Information
  - 6.12.3 Clinical Status and Trial Details
  - 6.12.4 Attribute Analysis
  - 6.12.5 Impact of Drug on the market
- 6.13 Stiolto Respimat
  - 6.13.1 Overview

- 6.13.2 Patent Information
- 6.13.3 Clinical Status and Trial Details
- 6.13.4 Attribute Analysis
- 6.13.5 Impact of Drug on the market
- 6.14 Daliresp/Daxas
  - 6.14.1 Overview
  - 6.14.2 Patent Information
  - 6.14.3 Clinical Status and Trial Details
  - 6.14.4 Attribute Analysis
  - 6.14.5 Impact of Drug on the market
- 6.15 Trelegy Ellipta
  - 6.15.1 Overview
  - 6.15.2 Patent Information
  - 6.15.3 Clinical Status and Trial Details
  - 6.15.4 Attribute Analysis
  - 6.15.5 Impact of Drug on the market
- 6.16 Trimbow
  - 6.16.1 Overview
  - 6.16.2 Patent Information
  - 6.16.3 Clinical Status and Trial Details
  - 6.16.4 Attribute Analysis
  - 6.16.5 Impact of Drug on the market
- 6.17 Arnuity Ellipta
  - 6.17.1 Overview
  - 6.17.2 Patent Information
  - 6.17.3 Clinical Status and Trial Details
  - 6.17.4 Attribute Analysis
  - 6.17.5 Impact of Drug on the market
- 6.18 Bevespi Aerosphere
  - 6.18.1 Overview
  - 6.18.2 Patent Information
  - 6.18.3 Clinical Status and Trial Details
  - 6.18.4 Attribute Analysis
  - 6.18.5 Impact of Drug on the market
- 6.19 Lonhala Magnair
  - 6.19.1 Overview
  - 6.19.2 Patent Information
  - 6.19.3 Clinical Status and Trial Details
  - 6.19.4 Attribute Analysis

- 6.19.5 Impact of Drug on the market
- 6.20 Revefenacin
  - 6.20.1 Overview
  - 6.20.2 Patent Information
  - 6.20.3 Clinical Status and Trial Details
  - 6.20.4 Attribute Analysis
  - 6.20.5 Impact of Drug on the market
- 6.21 PT010
  - 6.21.1 Overview
  - 6.21.2 Patent Information
  - 6.21.3 Clinical Status and Trial Details
  - 6.21.4 Attribute Analysis
  - 6.21.5 Impact of Drug on the market
- 6.22 Nucala
  - 6.22.1 Overview
  - 6.22.2 Patent Information
  - 6.22.3 Clinical Status and Trial Details
  - 6.22.4 Attribute Analysis
  - 6.22.5 Impact of Drug on the market
- 6.23 RPL554
  - 6.23.1 Overview
  - 6.23.2 Patent Information
  - 6.23.3 Clinical Status and Trial Details
  - 6.23.4 Attribute Analysis
  - 6.23.5 Impact of Drug on the market
- 6.24 Fasenra
  - 6.24.1 Overview
  - 6.24.2 Patent Information
  - 6.24.3 Clinical Status and Trial Details
  - 6.24.4 Attribute Analysis
  - 6.24.5 Impact of Drug on the market

## **7 PIPELINE ASSESSMENT**

- 7.1 Overview
- 7.2 Strategic Review of the Pipeline
- 7.3 Pipeline analysis by Phases of Development
  - 7.3.1 NDA/BLA Filed
  - 7.3.2 Phase III Pipeline



- 7.3.3 Phase II Pipeline
- 7.3.4 Phase I Pipeline
- 7.3.5 Preclinical Pipeline
- 7.3.6 Discovery Pipeline
- 7.4 Pipeline Analysis by Mechanism of Action
- 7.5 Pipeline Analysis by Novelty of Mechanism of Action
- 7.6 Suspended and Terminated products

## **8 MARKET OUTLOOK**

- 8.1 Major Markets Overview
  - 8.1.1 Sales Forecast (2018-2024)
  - 8.1.1 Patient Forecast (2018-2024)
- 8.2 Analysis by Country (Sales and Patients forecast 2018-2024)
  - 8.2.1 France
  - 8.2.2 Germany
  - 8.2.3 Italy
  - 8.2.4 Spain
  - 8.2.5 United Kingdom
  - 8.2.6 United States
  - 8.2.7 Japan
- 8.3 Key events
- 8.4 Key Growth Drivers and Barriers

## **9 SALES AND PATIENT FORECAST FOR KEY DRUGS (FORECASTS TILL 2024)**

- 9.1 Spiriva
  - 9.1.1 Value sales in USD for COPD Disease
  - 9.1.2 Value sales by key Geographies in USD
  - 9.1.3 Absolute Patient Numbers in COPD Disease
  - 9.1.4 Patient Numbers by key Geographies
- 9.2 Tudorza Pressair
  - 9.2.1 Value sales in USD for COPD Disease
  - 9.2.2 Value sales by key Geographies in USD
  - 9.2.3 Absolute Patient Numbers in COPD Disease
  - 9.2.4 Patient Numbers by key Geographies
- 9.3 Seebri Neohaler
  - 9.3.1 Value sales in USD for COPD Disease
  - 9.3.2 Value sales by key Geographies in USD

- 9.3.3 Absolute Patient Numbers in COPD Disease
- 9.3.4 Patient Numbers by key Geographies
- 9.4 Incruse Ellipta
  - 9.4.1 Value sales in USD for COPD Disease
  - 9.4.2 Value sales by key Geographies in USD
  - 9.4.3 Absolute Patient Numbers in COPD Disease
  - 9.4.4 Patient Numbers by key Geographies
- 9.5 Onbrez
  - 9.5.1 Value sales in USD for COPD Disease
  - 9.5.2 Value sales by key Geographies in USD
  - 9.5.3 Absolute Patient Numbers in COPD Disease
  - 9.5.4 Patient Numbers by key Geographies
- 9.6 Striverdi Respimat
  - 9.6.1 Value sales in USD for COPD Disease
  - 9.6.2 Value sales by key Geographies in USD
  - 9.6.3 Absolute Patient Numbers in COPD Disease
  - 9.6.4 Patient Numbers by key Geographies
- 9.7 Advair/Seretide
  - 9.7.1 Value sales in USD for COPD Disease
  - 9.7.2 Value sales by key Geographies in USD
  - 9.7.3 Absolute Patient Numbers in COPD Disease
  - 9.7.4 Patient Numbers by key Geographies
- 9.8 Symbicort Turbuhaler
  - 9.8.1 Value sales in USD for COPD Disease
  - 9.8.2 Value sales by key Geographies in USD
  - 9.8.3 Absolute Patient Numbers in COPD Disease
  - 9.8.4 Patient Numbers by key Geographies
- 9.9 Breo Ellipta
  - 9.9.1 Value sales in USD for COPD Disease
  - 9.9.2 Value sales by key Geographies in USD
  - 9.9.3 Absolute Patient Numbers in COPD Disease
  - 9.9.4 Patient Numbers by key Geographies
- 9.10 Ultibro/Utibron
  - 9.10.1 Value sales in USD for COPD Disease
  - 9.10.2 Value sales by key Geographies in USD
  - 9.10.3 Absolute Patient Numbers in COPD Disease
  - 9.10.4 Patient Numbers by key Geographies
- 9.11 Anoro Ellipta
  - 9.11.1 Value sales in USD for COPD Disease

- 9.11.2 Value sales by key Geographies in USD
- 9.11.3 Absolute Patient Numbers in COPD Disease
- 9.11.4 Patient Numbers by key Geographies
- 9.12 Brimica Genuair/Duaklir
  - 9.12.1 Value sales in USD for COPD Disease
  - 9.12.2 Value sales by key Geographies in USD
  - 9.12.3 Absolute Patient Numbers in COPD Disease
  - 9.12.4 Patient Numbers by key Geographies
- 9.13 Stiolto Respimat
  - 9.13.1 Value sales in USD for COPD Disease
  - 9.13.2 Value sales by key Geographies in USD
  - 9.13.3 Absolute Patient Numbers in COPD Disease
  - 9.13.4 Patient Numbers by key Geographies
- 9.14 Daliresp/Daxas
  - 9.14.1 Value sales in USD for COPD Disease
  - 9.14.2 Value sales by key Geographies in USD
  - 9.14.3 Absolute Patient Numbers in COPD Disease
  - 9.14.4 Patient Numbers by key Geographies
- 9.15 Trelegy Ellipta
  - 9.15.1 Value sales in USD for COPD Disease
  - 9.15.2 Value sales by key Geographies in USD
  - 9.15.3 Absolute Patient Numbers in COPD Disease
  - 9.15.4 Patient Numbers by key Geographies
- 9.16 Trimbow
  - 9.16.1 Value sales in USD for COPD Disease
  - 9.16.2 Value sales by key Geographies in USD
  - 9.16.3 Absolute Patient Numbers in COPD Disease
  - 9.16.4 Patient Numbers by key Geographies
- 9.17 Arnuity Ellipta
  - 9.17.1 Value sales in USD for COPD Disease
  - 9.17.2 Value sales by key Geographies in USD
  - 9.17.3 Absolute Patient Numbers in COPD Disease
  - 9.17.4 Patient Numbers by key Geographies
- 9.18 Bevespi Aerosphere
  - 9.18.1 Value sales in USD for COPD Disease
  - 9.18.2 Value sales by key Geographies in USD
  - 9.18.3 Absolute Patient Numbers in COPD Disease
  - 9.18.4 Patient Numbers by key Geographies
- 9.19 Lonhala Magnair

- 9.19.1 Value sales in USD for COPD Disease
- 9.19.2 Value sales by key Geographies in USD
- 9.19.3 Absolute Patient Numbers in COPD Disease
- 9.19.4 Patient Numbers by key Geographies
- 9.20 Revefenacin
  - 9.20.1 Value sales in USD for COPD Disease
  - 9.20.2 Value sales by key Geographies in USD
  - 9.20.3 Absolute Patient Numbers in COPD Disease
  - 9.20.4 Patient Numbers by key Geographies
- 9.21 PT010
  - 9.21.1 Value sales in USD for COPD Disease
  - 9.21.2 Value sales by key Geographies in USD
  - 9.21.3 Absolute Patient Numbers in COPD Disease
  - 9.21.4 Patient Numbers by key Geographies
- 9.22 Nucala
  - 9.22.1 Value sales in USD for COPD Disease
  - 9.22.2 Value sales by key Geographies in USD
  - 9.22.3 Absolute Patient Numbers in COPD Disease
  - 9.22.4 Patient Numbers by key Geographies
- 9.23 RPL554
  - 9.23.1 Value sales in USD for COPD Disease
  - 9.23.2 Value sales by key Geographies in USD
  - 9.23.3 Absolute Patient Numbers in COPD Disease
  - 9.23.4 Patient Numbers by key Geographies
- 9.24 Fasenra
  - 9.24.1 Value sales in USD for COPD Disease
  - 9.24.2 Value sales by key Geographies in USD
  - 9.24.3 Absolute Patient Numbers in COPD Disease
  - 9.24.4 Patient Numbers by key Geographies

## **10 APPENDIX**

- 10.1 Bibliography
- 10.2 Abbreviations
- 10.3 Coverage
- 10.4 Methodology and Research conducted
- 10.5 Market Forecast
- 10.6 About Pharmascroll
- 10.7 Contact Us

## 10.8 Disclaimer

## I would like to order

Product name: COPD: Disease Insights and Market Forecasts to 2024

Product link: <https://marketpublishers.com/r/C8C7A2488AEEN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8C7A2488AEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970